The aim of the present study was to explore whether there is enhanced endothelial dysfunction in patients developing acute GvHD (aGvHD) after allogeneic hematopoietic cell transplantation (allo-HCT) and to identify biomarkers with predictive and/or diagnostic value. In in vitro experiments, endothelial cells (ECs) were exposed to serum from patients with (aGvHD, n = 31) and without (NoGvHD, n = 13) aGvHD, to evaluate changes in surface adhesion receptors, the reactivity of the extracellular matrix by measuring the presence of Von Willebrand factor (VWF) and platelet adhesion, and the activation of intracellular signaling proteins. Plasma levels of VWF, ADAMTS-13, TNF receptor 1 (TNFR1), soluble vascular cell adhesion molecule 1 and soluble intercellular adhesion molecule 1 were also measured. In vitro results showed a more marked proinflammatory and prothrombotic phenotype in ECs in association with aGvHD. Regarding circulating biomarkers, levels of VWF and TNFR1 above an optimal cutoff score, taken independently or combined, at day 7 after allo-HCT, would be able to positively predict that around 90% of patients will develop aGvHD. Our results demonstrate that endothelial damage is aggravated in those allo-HCT recipients developing aGvHD, and that VWF and TNFR1 are promising predictive aGvHD biomarkers. These findings could contribute to improve the understanding of the pathophysiology of aGvHD.
INTRODUCTION
Acute GvHD (aGvHD) is the major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). 1, 2 Despite the benefits of this procedure being clear, allo-HCT is associated with several early complications in which endothelial dysfunction (ED) seems to have an etiopathogenic role. [3] [4] [5] [6] [7] [8] [9] aGvHD is caused by alloreactivity, defined as the donorimmunocompetent cell response against foreign recognized molecules, usually peptides, of the minor and major histocompatibility complex in the host. [10] [11] [12] The pathophysiology of aGvHD implies multiple tissue and organ damage, mainly affecting the liver, the gastrointestinal tract and/or the skin. 13 The first stage involves the effect of the conditioning regimen and the underlying disease on the host, with the activation of the recipient's APC as well as the release of cytokines and chemokines from the injured tissues. 14, 15 In a second stage, APC promote the proliferation and differentiation of donor T lymphocytes into CD4+ and cytotoxic T-cell lymphocytes, causing enhanced injury in the host target tissues and organs. 11, [15] [16] [17] Owing to their location, the role of endothelial cells (ECs) through all the events occurring before and during aGvHD becomes especially important because of their continuous exposure to the damaging executors from the immune system, inducing the expression of more antigenpresenting molecules and modifying their phenotype to a more activated and, eventually, dysfunctional one. 9, 18 The vascular endothelium is an active biological interface between the blood and all other tissues, maintains the blood fluidity, mediates the vasomotor tone and the hemostatic balance, and regulates the permeability of the vessel wall as well as the inflammatory reactions, among other functions. 19, 20 ECs have been found to operate in innate immunity by expressing Toll-like and NOD-like receptors. [21] [22] [23] They also seem to participate in the adaptive immunity by acting as secondary APC to activate circulatory effectors and to recruit leukocytes and platelets. 21 As we have previously demonstrated, the endothelium is injured early after HCT by the consecutive effects of the conditioning regimen, the proinflammatory agents used during transplantation, the translocation of endotoxins across the damaged gastrointestinal tract and the engraftment. 24, 25 Furthermore, the ED has been proposed as the prime contributor to the proinflammatory, procoagulant and proapoptotic phenotype developing in HCT recipients suffering from some early complications. [7] [8] [9] 26, 27 At this point, the host vascular endothelium is also the first barrier that comes into contact with the damaging inputs occurring before the debut of aGvHD. 9, 28, 29 The aim of the present study was to investigate if the endothelial damage associated with allo-HCT is more severe in those patients who develop aGvHD as compared with patients without, by using a well-established experimental model developed in our laboratory. 24, 25 In an in vitro approach, EC in culture were exposed to serum samples from patients receiving an allo-HCT non-developing or developing aGVHD to evaluate the differential expression of a dysfunctional phenotype. In addition, ex vivo measurements of endothelial damage circulating molecules were carried out to confirm the in vitro results and to further investigate their value as aGvHD biomarkers. 1 
METHODS

Experimental design
In vitro and ex vivo experiments were performed using serum and plasma samples, respectively, from patients developing or not aGvHD after allo-HCT. Blood samples were obtained before the conditioning regimen (Pre), immediately before the transplantation (day 0) and at days 7, 14, 21 and 28 after allo-HCT.
For the in vitro studies, human microvascular ECs (HMEC-1; ATCC, Manassas, VA, USA) were grown with media containing 20% pooled sera from patients in each group, to evaluate changes in: (a) intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) at the cell surface; (b) von Willebrand factor (VWF) in the extracellular matrix (ECM); (c) the reactivity of ECM towards circulating platelets; and (d) the activation of the mitogen-activated protein kinases (MAPKs) p38, SAPK/JNK and Erk 1/2. 30, 31 Plasma levels of VWF, ADAMTS-13, the receptor 1 for TNFα (TNFR1), soluble VCAM-1 (sVCAM-1) and soluble ICAM-1 (sICAM-1) were measured in each patient as potential biomarkers of ED.
Patients
Two groups of allo-HCT recipients were included consecutively (2008-2010) as follows: (i) patients who developed aGVHD grade II-IV during the first 3 months after allo-HCT (n = 31) and (ii) patients without aGvHD (NoGvHD group, n = 13). Patients developing aGvHD were separated in four subgroups, depending on the onset day: between day 7 and 14 (G14, n = 10), day 14 and 21 (G21, n = 6), day 21 and 28 (G28, n = 6), and from day 28 (G428, n = 9) post allo-HCT. Patients characteristics are provided in Table 1 . Patients with other early complications associated with allo-HCT such as veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), thrombotic microangiopathy (TMA), capillary leak syndrome or engraftment syndrome were excluded for this study.
Immunofluorescence detection of ICAM-1, VCAM-1 and VWF EC cultured in eight-well microplates (Nunk Labtek, Madrid, Spain) were exposed to the media under study for 48 h. Monolayers were incubated with specific monoclonal antibodies anti-ICAM-1 and anti-VCAM-1 (SantaCruz Biotech, Dallas, TX, USA). To obtain ECM, cells grown on 18 × 18 mm 2 glass coverslips were extracted with 6% ethyleneglycoltetraacetic acid (1 h, 37°C). ECM were fixed and incubated overnight at 4°C with a polyclonal antibody anti-VWF (Dako, Glostrup, Denmark). 31 Images were captured using an epifluorescent microscope (DM4000 B, Leica, Barcelona, Spain). Fluorescent micrographs were analyzed densitometrically using Image J Fiji software (Bethesda, MD, USA). This software automatically analyzes the gray density of each pixel in a scale ranging from 0 (black) to 255 (white) using a standard filter to determine the threshold. The fluorescence intensity was measured only in the selected area in 20 different fields per well by this automated system, allowing the objectivity of the quantification. Blind evaluation was performed by independent technicians.
Adhesion studies under flow conditions ECM-coated coverslips were exposed to citrated blood through a parallelplate perfusion chamber (800/s, 5 min). 25 The surface covered by platelets (%SC) was quantified en face using the same approach described above (Image J Fiji).
Phosphorylation of MAPK proteins
EC monolayers (starved for 24 h) were exposed to the serum pools (15 min). Changes in MAPK proteins were evaluated using specific antibodies against phosphorylated p38, SAPK/JNK and Erk 1/2 (Cell Signaling, Danvers, MA, USA), as previously described. 25, 32 β-Actin (Cell signaling), a protein that remains constant under the tested conditions, was selected as a loading control. Results are expressed as fold increase of the phosphorylated protein from GvHD groups vs NoGvHD groups.
Soluble biomarkers of endothelial damage VWF (Grifols, Barcelona, Spain), TNFR1 (BosterBio, Pleasanton, CA, USA), sICAM-1 (PeproTech, London, UK) and sVCAM-1 (R&D Systems, Minneapolis, MN, USA) were measured in plasma from individual patients by ELISA. ADAMTS-13 activity (Technoclone, Viena, Austria) was analyzed by the FRETS-VWF73 assay. 33 
Statistical analysis
In vitro results were analyzed by Student's t-test for paired data. For the ex vivo results, the global data of all cohort patients at all-time points were analyzed using Wilcoxon rank test and the one-way analysis of variance to confront each experimental point vs day Pre. Diagnostic performance of biomarkers was evaluated by measuring the area under the curve (AUC) from the receiver operating characteristic (ROC) curves. 34, 35 Composite panel for VWF and TNFR1 resulted from a logistic regression, categorizing the independent variable (1 = aGvHD, 0 = NoGvHD). Positive and negative predictive values (PPV and NPV) were estimated from data extrapolated from the resulted ROC curves, considering two different cutoff points: the neutral cutoff (median value) and the optimal cutoff (derived from the best likelihood ratio, LR). The statistical analysis was performed by EMF and supervised by AP.
Ethical aspects
This study was approved by the 'Ethics committee of the Hospital Clinic of Barcelona' (CEIC 2008/3353) and performed in accordance with the principles of the Declaration of Helsinki.
RESULTS
Expression of VCAM-1 and ICAM-1 on the cell surface in response to aGvHD sera There was an increased expression of both receptors in cells exposed to sera from G14, G21 and G28 compared with the corresponding NoGVHD samples. VCAM-1 expression, (mean fluorescence intensity ± s.e.m.), was 38.4 ± 9.2 vs 29.5 ± 7.7 at day 14, 36.2 ± 5.3 vs 20.5 ± 4.1 at day 21 and 45.3 ± 2.7 vs 38.7 ± 2.6 at day 28, n = 5, P o 0.05 and P o0.01 ( Figure 1a ). Similar results were obtained for ICAM-1 expression (42.2 ± 2.6 vs 31.5 ± 2.8 at day 14, 37.2 ± 2.4 vs 28.2 ± 1.3 at day 21 and 36.8 ± 3 vs 26.1 ± 2 at day 28, n = 5, P o0.05) (Figure 1b) .
Thrombogenicity of the ECM generated by cells grown with aGvHD sera The %SC on perfused ECM from EC exposed to sera from aGvHD groups was slightly superior to that observed in response to sera from NoGvHD groups (47.3% ± 4.8% vs 42.9% ± 4.3% at day 14, 42% ± 3.8% vs 38.4% ± 4.1% at day 21 and 33.3% ± 0.2% vs 24.9% ± 1.8% at day 28, n = 5, P o 0.05 and Po 0.01) (Figure 2a ).
VWF expression in ECM from EC exposed to aGvHD recipients sera was enhanced in comparison with the control group (mean fluorescence intensity ± s.e.m. of 47.4 ± 8 vs 34.9 ± 4.3 at day 14, 35.8 ± 4.7 vs 30.9 ± 2.7 at day 21 and 52.1 ± 1.2 vs 32.6 ± 1.7 at day 28, n = 5, P o 0.05 and P o0.01) (Figure 2b ).
Phosphorylation of MAPK proteins
Phosphorylation of p38 (n = 4) in EC was clearly stronger in the aGvHD group than in NoGvHD (1.4 ± 0.1 vs 1 at day 14, P o 0.01, 1.25 ± 0.1 vs 1 ± at day 21, P o 0.05, and 1.34 ± 0.25 vs 1 at day 28) (Figure 3 ). The same tendency was found for phospho-SAPK/JNK and phospho-Erk1/2 (Figure 3 ), although the differences between groups did not reach statistical significance (n = 4).
Measurement of endothelial damage biomarkers before and at the aGvHD onset Data obtained at day Pre, 0 and 7 included all patients: NoGvHD patients (n = 13) and patients that developed aGvHD (n = 31). Importantly, the values at day 14, 21 and 28 correspond to n = 13 patients from the NoGvHD group and only to the day of aGvHD debut for the subgroups developing this complication, being n = 10 for G14, n = 6 for G21 and n = 6 for G28.
Plasma levels of VWF in aGvHD patients were significantly elevated in comparison with NoGvHD patients at all points, except at day 0 (Figure 4a ). Although at day 7 after transplantation no patient developed aGvHD, VWF levels were consistently higher in (Figure 4a and Supplementary  Table S1) . TNFR1 values were superior in patients with aGvHD at day 7, 14, 21 and 28, although only statistical significant at the onset day of G14 (P o 0.01). When values were confronted to day Pre for each independent group (aGvHD or NoGvHD), only values at day 7 of the aGvHD group and the onset day 21 of the G21 group were significant (P o0.05) (Figure 4b and Supplementary Table S1 ).
ADAMTS-13 activity in aGvHD patients was lower than in NoGvHD patients, especially at days 0 and 7 (Po0.001) and at day 14 for G14 group (Po0.05). When comparing ADAMTS-13 activity at all time points vs day Pre, only values in patients from G14 at day 14 were significant (Po0.01). sICAM-1 and sVCAM-1 levels did not change substantially among the groups under study, when comparing values after HCT vs day Pre, although results were statistically significant at some points ( Figure 4 Ci-iii; Supplementary Table S1).
VWF and TNFR1: potential diagnostic biomarkers of aGvHD Independent evaluation of the AUC for all biomarkers was performed by using ROC curve analysis, using each biomarker measurement at the aGvHD onset (for G14, G21 and G28, n = 22) vs NoGvHD (n = 13) at the same time point. The AUC was 0.81 for VWF (95% confidence interval = 0.69-0.93, P = 0.0002) (Figure 5a ) and 0.71 for TNFR1 (95% confidence interval = 0.57-0.86, P o0.01) (Figure 5b ). The logistic regression determined that the AUC of the diagnostic panel composed by VWF and TNFR1 was 0.78 (95% confidence interval = 0.64-0.91) (Figure 5c and Supplementary Table S1 ).
The AUCs obtained for ADAMTS-13 activity, sICAM-1 and sVCAM-1 never reached values superior to 0.70.
VWF and TNFR1 as predictors of aGvHD Levels of VWF and TNFR1 were measured 7 days before the onset. The combination of both biomarkers with levels over the optimal cutoff value achieved an NPV of 64%, although with a PPV of 40% (Supplementary Table S2 ).
The usefulness of VWF and TNFR1 as predictors of aGvHD at day 7 post HCT was also determined because (a) levels at day 7 were consistently higher in aGvHD patients (Figure 4a and b) and (b) AUCs at aGvHD onset day were 40.70. When VWF was analyzed as a single biomarker, the outcomes revealed that 82% of patients with VWF levels above the neutral cutoff (276.5%, LR = 1.5), at day 7 after HCT, will develop aGvHD during the following 100 days. Moreover, regarding the optimal cutoff (339.5%, LR = 5.6), the PPV was 93%. The NPV for the two cutoff points considered were 37% and 39%, respectively. For the TNFR1 test, the PPV at day 7 after allo-HCT was 80% when considering the neutral cutoff Abbreviations: aGvHD = acute GvHD; Allo-HCT = allogeneic hematopoietic cell transplantation; cGvHD = chronic GvHD; CyA = cyclosporine A; HL = Hodgkin lymphoma; MAC = myeloablative conditioning; MTX = methotrexate; MMF = mycophenolate mofetil; NHL = non-hodgkin lymphoma; PCD = plasma cell disease; PLL = prolymphocytic leukemia; RIC = reduced intensity conditioning. a One case with CD34+ selection.
Endothelial damage matches and could predict aGVHD E Mir et al (6200 pg/ml, LR 1.4) and 93% for the optimal one (7574 pg/ml, LR 4.48). The NPV was 32% for the neutral and 36% for the optimal cutoff ( Figure 5e and Supplementary Table S2 ). Supplementary Table S2 summarizes the outcomes of VWF and TNFR1 measured at day 7 after allo-HCT as predictors of aGvHD. Both biomarkers combined showed PPV and NPV of 90% and 37%, considering the optimal cutoff, respectively (Figure 5e ). It should be indicated that although the PPV obtained independently for both VWF and TNFR1 were 93%, the combined PPV was 90% due to the fact that in two patients only one of the biomarkers was measured. Furthermore, the logistic regression performed to develop the predictive composite panel at day 7 after allo-HCT Figure 2. Higher reactivity of the EC ECM towards platelets in response the sera from patients with aGvHD. (a) Representative images of platelet adhesion after exposing ECM to flowing blood (800/s, 5 min). ECM were generated by EC exposed to sera from both GvHD (G21) and NoGvHD groups at day 21 after allo-HCT. Bar diagrams show the surface covered by platelets (% SC) for groups G14, G21, G28 (black bars) and the corresponding days for the NoGvHD group (white bars). Values are expressed as % ± s.e.m., *P o0.05 and **Po0.01. (b) Micrographs show the presence of VWF (green staining with polyclonal rabbit antihuman VWF labeled with Alexa 488) on the ECM produced by EC exposed to sera from both GvHD (G21) and NoGvHD groups at day 21 after allo-HCT. Bar diagrams show the quantitative data expressed as mean fluorescence intensity (MFI) ± s.e.m., *Po0.05 and **Po0.01. Results correspond to n = 5 experiments. Original magnification of × 400 for all micrographs obtained with a light microscope (LEICA DM4000B).
Endothelial damage matches and could predict aGVHDusing VWF and TNFR1 values at this point computed an AUC of 0.68 (95% confidence interval = 0.50-0.86) (Figure 5d and Supplementary Table S1 ).
DISCUSSION
We have differentially explored the activation and damage of ECs in association with aGvHD development. The results obtained demonstrate that patients developing aGvHD exhibit an enhanced degree of ED in comparison with patients who do not develop this complication. The humoral factors present in the blood at the day of aGvHD diagnosis induced a more marked proinflammatory and prothrombotic state on ECs in culture. Moreover, ex vivo measurements of endothelial derived biomarkers confirmed the differential degree of endothelial damage between patients with and without aGvHD, starting to be detectable 7 days after HCT. Soluble levels of VWF and TNFR1 at day 7 after HCT would be able to positively predict that almost 90% of patients expressing plasma levels above an optimal cutoff score will develop aGvHD. Our results relate aGvHD to a strong injury of the endothelium and this endothelial damage appears some days before the clinical diagnosis of aGvHD onset. Owing to its location, the endothelium is surely a main target of the 'cytokine storm' and the activation of the immune system, both probably inducing a dysfunctional behavior of ECs. In addition, the endothelium is a perfect candidate to participate in all the events occurring before and during aGvHD. In previous studies, Salat et al., 27 Luft et al. 28 and Almici et al. 36 suggested the presence of endothelial damage during aGvHD, as they found elevated circulating biomarkers in patients with this complication.
We have investigated the proinflammatory and prothrombotic effects of the serum from patients developing or not aGvHD, on cultured ECs. Our results indicate that the humoral factors present in aGvHD developing patients, at the onset day, provoke an increased expression of adhesion receptors at the cell surface superior to that observed in cells exposed to sera from patients without aGvHD. In an aGvHD scenario, this effect could facilitate the infiltration of leukocytes, more specifically T lymphocytes, through the endothelial barrier. 37, 38 In addition, ECs can shift to a prothrombotic phenotype, by modifying the composition of the ECM generated, depending on their environmental conditions. Exposure of ECs to the circulating humoral conditions in allotransplant recipients results in the generation of a more prothrombotic ECM, enriched with VWF and tissue factor. 25 During the development of aGvHD, blood-borne cells, such as macrophages and neutrophils, become strongly activated promoting T-lymphocyte differentiation and expansion, in which activation of the inflammation related protein p38 has an important role. 39 According to our present results, EC also respond to the injury caused by the humoral factors present in the serum from patients developing aGvHD increasing the activation of p38 significantly. Similar results were achieved with phospho-SAPK/ JNK, related to apoptosis, and phospho-Erk1/2, protein that promotes cell proliferation, survival and differentiation, and could constitute a natural defense mechanism of the endothelium during the aGvHD. [39] [40] [41] The ROC curves analysis allowed us to elucidate the most appropriate biomarkers of endothelial damage. Only VWF and TNFR1 achieved AUC40.70 at the aGvHD onset day. VWF is produced by EC and secreted after either an acute or a persistent 
G14
G21 G28 Figure 3 . Differential activation of the signaling molecules phospho-p38 MAPK, phospho-SAPK/JNK and phospho-Erk 1/2 in ECs exposed to sera from aGvHD patients. EC were exposed to pooled sera from groups G14, G21 and G28 (onset days of aGvHD), and from the NoGvHD group at days 14, 21 and 28, respectively. The differential expression of activated phospho-p38 MAPK, phospho-SAPK/JNK and phosphoErk1/2 was measured and expressed by bar diagrams in fold increase in cells exposed to sera from GvHD groups vs the expression of the same phosphorylated proteins in cells exposed to sera from the NoGvHD group (dashed line). *P o0.05 and **P o0.01. Images are representative of n = 4 western blotting experiments. Figure 4 . Kinetics of circulating markers of endothelial damage in plasma from patients in aGvHD and NoGvHD groups. Plasma levels of VWF, TNFR1, ADAMTS-13, sICAM-1 and sVCAM-1 were analyzed in plasma samples collected at days Pre, 0, 7, 14, 21 and 28 from patients that developed aGvHD and compared with values in patients that did not developed this complication (NoGvHD). Values shown correspon to days Pre, 0 and 7 include the total number of patients from aGvHD (n = 31, black boxes) and NoGvHD (n = 13, white boxes) groups. For days 14, 21 and 28, values correspond to those obtained in patients from G14 (n = 10), G21 (n = 6) and G28 (n = 6), respectively, and were confronted to values in the NoGvHD group (n = 13), at the respective day. Raw data of VWF levels (a) and TNFR1 levels (b) measured in plasma are represented through box-and-whiskers plots and the corresponding heat maps. (c) Box-and-whiskers plots represent the changes in soluble levels of ADAMTS-13 activity, sICAM-1 and sVCAM-1(Ci-iii). *P o0.05 and **P o0.01 when comparing aGvHD vs NoGvHD and #P o0.01 and ##P o0.0001 when confronting values in each group vs the respective day Pre.
injury, as it occurs in HCT. 42 Soluble TNFR1 acts as an inhibitor of TNFα activity and represents a natural protective mechanism against the cytotoxic effect of this protein by preventing its binding to the surface receptors. TNFR1 seems to be regulated not only by the presence of TNFα but also by other proinflammatory mechanisms. 43 TNFα targets macrophages, monocytes, NK and activated T cells, and also ECs, eliciting a wide variety of inflammation-related intracellular responses, including the activation of nuclear factor-κB and MAPK pathways. [44] [45] [46] [47] These findings provide a new understanding of the pathophysiology of aGvHD, as they indicate that there is an enhanced endothelial vulnerability even before the aGvHD debut. 48 The results are in agreement with previous observations correlating aGvHD and chronic GvHD with high VWF levels in plasma. 26, 27 The present study goes an step further demonstrating that VWF levels are elevated even earlier than the onset. Therefore, there may be a previously unrecognized role for VWF as predictive biomarker of aGvHD. Concerning TNFR1, this biomarker has already been Figure 5 . ROC curves analysis and predictive values for the potential endothelial damage biomarkers evaluated. ROC curves analysis of VWF (a) and TNFR1 (b) at their respective onset days corroborated that patients developing aGvHD show a more marked dysfunctional profile than those that did not developed aGvHD (Po0.001 and Po 0.01, respectively). The composite panels of VWF and TNFR1 at the onset day of aGvHD (c) and at day 7 post allo-HCT (d) are depicted as AUC in a 95% confidence interval (CI). (e) Bar diagrams represent the PPVs and the NPVs when the optimal cutoff score is considered.
studied during recent years. 43, 49, 50 We have also explored the relation between TNFR1 levels and the endothelial damage, and activation state in patients undergoing allo-HCT. Our results are in line with previous observations by Choi et al. 49 proposing this biomarker as a good predictor of the severity and incidence of aGvHD. TNFR1 was included in two panels of aGvHD biomarkers: with hepatocyte growth factor, interleukin 2 receptor-α and interleukin 8, in one of the panels, and in combination with the suppression of tumorigenicity 2 and the regenerating islet-derived 3α in the other. 43, 50 Through the current data we also confirm that TNFR1 is a good ED marker with predictive and diagnostic capacity. In addition, it is interesting to point out that both VWF and TNFRI are feasible to be measured. Furthermore, VWF is routinely analyzed in diagnostic laboratories. Based on predictive values obtained from the ROC curves of both markers, the use of the optimal cut-off score at day 7 post HCT may provide a potential tool to predict the initiation of aGvHD.
Our results suggest that aGvHD is associated with enhanced activation and damage of ECs, changing their phenotype to a more proinflammatory and prothrombotic one. The composite panel of VWF and TNFR1 levels in plasma at day 7 after HCT may constitute good and simple predictors of the development of aGvHD. The ability of the biomarker panel to predict aGvHD development is particularly interesting. To validate their utility as biomarkers of aGvHD, evaluation in a higher number of patients and a validation cohort is required. In addition, further studies using animal models of disease are needed to clearly demonstrate that ED has a role in the pathophysiology of aGvHD. The endothelial damage in association with HCT may constitute an emerging target for future investigations of preventive and/or treatment therapies.
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